Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Pathology consultation on monitoring direct thrombin inhibitors and overcoming their effects in bleeding patients.

Winkler AM, Tormey CA; Education Committee of the Academy of Clinical Laboratory Physicians and Scientists.

Am J Clin Pathol. 2013 Nov;140(5):610-22. doi: 10.1309/AJCP9VJS6KUKNCHW. Review.

PMID:
24124139
2.

Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient.

Miyares MA, Davis K.

Am J Health Syst Pharm. 2012 Sep 1;69(17):1473-84. doi: 10.2146/ajhp110725. Review. Erratum in: Am J Health Syst Pharm. 2012 Nov 15;69(22):1943.

PMID:
22899742
3.

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A.

Thromb Haemost. 2010 Jun;103(6):1116-27. doi: 10.1160/TH09-11-0758. Epub 2010 Mar 29. Review.

PMID:
20352166
4.

The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.

Alikhan R, Rayment R, Keeling D, Baglin T, Benson G, Green L, Marshall S, Patel R, Pavord S, Rose P, Tait C.

Emerg Med J. 2014 Feb;31(2):163-8. doi: 10.1136/emermed-2012-201976. Epub 2013 Feb 22. Review.

5.

Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors.

Van Cott EM, Roberts AJ, Dager WE.

Semin Thromb Hemost. 2017 Apr;43(3):270-276. doi: 10.1055/s-0036-1597297. Epub 2017 Jan 4. Review.

PMID:
28052306
6.

Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.

Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, Taylor JM, Whinna HC, Winkler AM, Moll S.

J Thromb Haemost. 2013 Aug;11(8):1493-502. doi: 10.1111/jth.12308.

7.

Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.

Pehrsson S, Johansson K, Kjaer M, Elg M.

Thromb Haemost. 2010 Dec;104(6):1242-9. doi: 10.1160/TH09-10-0744. Epub 2010 Aug 30.

PMID:
20806126
8.

Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants.

Liew A, Eikelboom JW, O'Donnell M, Hart RG.

Can J Cardiol. 2013 Jul;29(7 Suppl):S34-44. doi: 10.1016/j.cjca.2013.04.013. Review.

PMID:
23790596
9.

Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.

Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM.

Thromb Haemost. 2012 May;107(5):985-97. doi: 10.1160/TH11-11-0804. Epub 2012 Mar 22.

PMID:
22438031
10.

Contemporary Anticoagulation Reversal Focus on Direct Thrombin Inhibitors and Factor Xa Inhibitors.

Mancl EE, Crawford AN, Voils SA.

J Pharm Pract. 2013 Feb;26(1):43-51. doi: 10.1177/0897190012465989. Epub 2012 Nov 16. Review. Erratum in: J Pharm Pract. 2013 Jun;26(3):347.

PMID:
23160865
11.

Pathology consultation on anticoagulation monitoring: factor X-related assays.

Wool GD, Lu CM; Education Committee of the Academy of Clinical Laboratory Physicians and Scientists.

Am J Clin Pathol. 2013 Nov;140(5):623-34. doi: 10.1309/AJCPR3JTOK7NKDBJ. Review. Erratum in: Am J Clin Pathol. 2013 Jun;141(6):899.

PMID:
24124140
12.

Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?

Curvers J, van de Kerkhof D, Stroobants AK, van den Dool EJ, Scharnhorst V.

Am J Clin Pathol. 2012 Oct;138(4):551-8.

PMID:
23010710
13.

Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays.

van Ryn J, Grottke O, Spronk H.

Clin Lab Med. 2014 Sep;34(3):479-501. doi: 10.1016/j.cll.2014.06.008. Epub 2014 Jul 22. Review.

PMID:
25168938
14.

Laboratory monitoring of new anticoagulants.

Castellone DD, Van Cott EM.

Am J Hematol. 2010 Mar;85(3):185-7. doi: 10.1002/ajh.21607. Review.

15.

Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.

Steiner T, Böhm M, Dichgans M, Diener HC, Ell C, Endres M, Epple C, Grond M, Laufs U, Nickenig G, Riess H, Röther J, Schellinger PD, Spannagl M, Veltkamp R.

Clin Res Cardiol. 2013 Jun;102(6):399-412. doi: 10.1007/s00392-013-0560-7. Epub 2013 May 14. Review.

PMID:
23669868
16.

[Monitoring of Oral Thrombin Inhibitor].

Matsuno K, Usami T, Hatuse M, Shimizu C.

Rinsho Byori. 2014 Oct;62(10):958-64. Review. Japanese.

PMID:
27526541
17.

Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?

Dickneite G, Hoffman M.

Thromb Haemost. 2014 Feb;111(2):189-98. doi: 10.1160/TH13-05-0431. Epub 2013 Oct 17. Review.

PMID:
24136202
18.

Methods for the monitoring of direct thrombin inhibitors.

Hafner G, Roser M, Nauck M.

Semin Thromb Hemost. 2002 Oct;28(5):425-30. Review.

PMID:
12420237
19.

Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis.

Salmela B, Joutsi-Korhonen L, Armstrong E, Lassila R.

Semin Thromb Hemost. 2012 Feb;38(1):23-30. doi: 10.1055/s-0031-1300948. Epub 2012 Feb 7. Review.

PMID:
22314600
20.

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J.

Am J Hematol. 2012 May;87 Suppl 1:S141-5. doi: 10.1002/ajh.23202. Epub 2012 Apr 4. Review. Erratum in: Am J Hematol. 2012 Jul;87(7):748.

Supplemental Content

Support Center